APIMEDS PHARMACEUTICALS US, INC. Operating Lease Right-of-Use Assets
APIMEDS PHARMACEUTICALS US, INC. (APUS) had Operating Lease Right-of-Use Assets of $156.16 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-14
- 2026-06-30: Operating Lease, Right-of-Use Asset $156.16K.
- 2026-03-31: Operating Lease, Right-of-Use Asset $171.78K.
- 2025-12-31: Operating Lease, Right-of-Use Asset $187.40K.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $156.16K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $171.78K 10-Q · filed 2026-05-26 |
| 2025-12-31 | $187.40K 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |